Among these methods, 16a-[18F]-fluoro-17b-estradiol (FES) PET/CT is capable of accurately localizing tumor lesions expressing ERα, and also of predicting ET sensitivity in patients with advanced HR+ BC [124]. The gene discussed is ESR1; the disease is breast cancer.